Phase III DeLLphi-304 results show T-cell engager Imdelltra (tarlatamab) delivers superior overall survival, improved ...

Download to gain expert insights and data-driven analysis from the ASCO 2025 Annual Meeting. This report covers key ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

ASCO Data Shows New Therapy Extends Survival in Small Cell Lung Cancer. Here's what you need to know about the new ...

It sounds too simple to be true. Exercise works just as effectively as a drug to slash the risk of dying from bowel cancer, ...

Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...

For the first time in years, small cell lung cancer (SCLC) patients have reason for renewed hope as more treatment options ...

Amgen (NasdaqGS:AMGN) recently announced interim results from its Phase 3 DeLLphi-304 trial for IMDELLTRA, showing significant improvement in survival outcomes for SCLC patients. This announcement ...

Tarlatamab prolonged both overall and progression-free survival in the treatment of small cell lung cancer, backing it as a ...

Breast cancer study results impressed at this year’s meeting, but raised new questions. Doctors also wrestled with how best ...

Presented at ASCO 2025, new data from the DESTINY-Breast09 trial showed that Enhertu plus pertuzumab cut the risk of disease progression or death by 44% compared to taxane, trastuzumab, and pertuzumab ...

New hope is on the horizon in the fight against cancer. At this year’s American Society of Clinical Oncology (ASCO) annual ...